Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical
company focused on advanced wound care, announced today that Edward J.
Quilty, the Company’s chief executive officer, will present a corporate
overview and update at the Lazard Capital Markets 9th Annual
Healthcare Conference taking place in New York City November 13 - 14,
2012 at the Pierre Hotel. The Company’s presentation will take place on
Tuesday, November 13, 2012 at 3:00 p.m. ET.
To listen and view the presentation investors may visit the investor
relations section of Derma Sciences’ website at www.dermasciences.com.
An archived copy of the presentation will also be available on Derma
About Derma Sciences, Inc.
Derma Sciences is a medical technology company focused on three segments
of the wound care marketplace: pharmaceutical wound care products,
advanced wound care dressings and traditional dressings. Derma Sciences
has successfully completed a Phase 2 clinical trial in diabetic foot
ulcer healing with DSC127, an investigational pharmaceutical drug under
development for the healing of diabetic foot ulcers, and is preparing to
begin Phase 3 clinical trials. Its MEDIHONEY® product is the leading
brand of honey-based dressings for the management of wounds and burns.
The product has been shown to be effective in a variety of indications,
and was the focus of a positive large-scale, randomized controlled trial
involving 108 subjects with leg ulcers. Other novel products introduced
into the $14 billion global wound care market include XTRASORB® for
better management of wound exudate, BIOGUARD® for infection prevention
and TCC-EZ™, a gold-standard treatment for diabetic foot ulcers.